Compass Pathways shares depression survey results, teeing up potential first psilocybin approval. November 02, 2026 Compass Pathways, in partnership with the Depression and Bipolar Support Alliance (DBSA), released a new report summarizing findings from a national survey of people living with treatment-resistant depression (TRD), revealing the extent of unmet need for people living with the condition. The survey highlighted the self-reported realities of living with a condition that can profoundly affect daily life, revealing the burden of prolonged depressive episodes without meaningful relief. In the survey, 95% of patients (n=261) described themselves as either functioning but struggling, surviving day-to-day or barely getting by. Most patients (almost 75%) feel that they have tried all available treatment options and are emotionally exhausted from trying treatments that have not worked. Compass Pathways could become the first company to secure FDA approval for a psilocybin-based treatment, with its lead candidate, COMP360, under evaluation for TRD and post-traumatic stress disorder (PTSD). The investigational synthetic psilocybin treatment has received FDA breakthrough therapy designation and the UK's innovative licensing and access pathway (ILAP) designation for TRD. An update on COMP360 is anticipated November 3, when Compass reports its third-quarter results. At last update, the company was advancing a rolling NDA submission, with final submission targeted for Q4 2026. Current issue. 2026 annual buyer's guide. Get started here for your complimentary print or digital subscription Follow Tablets & Capsules.

Compass Pathways: A high-stakes bet on psilocybin. Last updated: October 28, 2026 Compass Pathways is completing the final filings for COMP360, a synthetic psilocybin pill intended for treatment-resistant depression. According to Business Insider, FDA approval could come as soon as next year. Rejection would expose a company whose launch preparations, workforce and valuation are concentrated around a single product. * COMP360 is a synthetic psilocybin treatment for treatment-resistant depression. * FDA approval is possible as soon as next year. * Compass has added 150 employees and expanded its marketing operation. * The company operates from a new Jersey City office. * CEO Kabir Nath took the executive role after leaving a pharmaceutical company in 2022. From pharmaceutical executive to startup risk. Kabir Nath joined Compass after receiving a call from a startup developing a synthetic version of psilocybin. He left a secure pharmaceutical leadership position because he believed the compound could help people whose depression had not responded to conventional antidepressants. The decision carried personal weight after his father died by suicide. But the commercial challenge remained formidable: Compass needed regulatory approval, a successful launch and enough financial endurance to support a new medicine. Its preparations suggest management believes that day is approaching. The company has added 150 people, expanded marketing and moved into new office space in Jersey City. Those are costly commitments made before approval is assured. That creates the central leadership tension. Compass is building an organization for a future launch while investors still price the possibility of failure. Product, workforce and share price now depend heavily on one regulatory decision. Approval would not end the risk. A ketamine-based treatment from a Johnson & Johnson subsidiary received FDA approval for depression patients in 2019. Compass is pursuing approval for a different compound with a more traditional psychedelic profile. That precedent offers encouragement, not a template. Even a favorable regulatory decision would shift the risk rather than eliminate it. Broad adoption, clinician familiarity, reimbursement and a commercially sustainable price would become more important after approval. Compass would also need to translate its treatment protocol into a repeatable model. In trials, patients receive the pill in a quiet clinical setting with music and a clinician present for safety; the experience is not directed as psychotherapy. The history helps explain why both the opportunity and the resistance are substantial. Public experimentation and countercultural adoption preceded psilocybin's classification as a Schedule I substance in 1970, which restricted even research. The FDA permitted researchers at Johns Hopkins University to study it in 2000. Research later entered a biotech boom from 2018 to about 2022 that produced hundreds of psychedelic companies. Compass received breakthrough therapy designation for its formulation in 2018 and later began testing the drug in people. Its analysis. COMP360 is a single-product biotechnology story with unusually personal stakes. Leadership expertise can improve execution, but it cannot diversify away a binary regulatory outcome. Business Insider reported that investors would likely sell shares sharply if Compass were denied approval, potentially pushing the company toward bankruptcy. Patients are exposed to a different side of the same concentration. Compass says four million Americans with depression are not helped by traditional antidepressants such as SSRIs. That large potential need does not guarantee demand for COMP360, but it explains why Nath and the company frame the mission as substantial. The share-price history shows how sentiment has moved with clinical and regulatory expectations. Shares closed around $11 on the referenced Friday, up $5 from a year earlier but below the $17 public offering price in 2020. | Scenario | Strategic shift | What matters most | | Approval | The launch thesis advances, and commercial execution becomes central | Adoption, access and the conversion of regulatory progress into sustainable operations | | Delay | The launch moves while preparation costs continue | Financial endurance, hiring discipline and management's ability to revise the timeline | | Rejection | The core commercial thesis weakens sharply | Investor confidence, available resources and whether Compass can continue pursuing the treatment | Leadership under a binary outcome. Nath's choice to leave traditional pharma was presented as both principled and risky. Compass now needs an operating model that recognizes the same tension: prepare for launch, but avoid turning every possible future into a fixed cost today. Hiring, office expansion and marketing investment can create momentum ahead of approval. They can also magnify losses if approval is delayed or denied. The distinction between conviction and overextension is therefore not motivational; it is financial. For investors, the crucial evidence will extend beyond an approval headline. The quality of the regulatory decision, the pace of launch preparation and Compass's ability to withstand delay matter more than a single optimistic forecast. For patients, the practical question is whether an experimental treatment can become accessible without losing the controlled setting that distinguishes COMP360 from recreational psychedelic use. Compass has assembled much of the organization required for a launch. Its harder task may be preserving enough flexibility to survive if the launch arrives late - or never. Key takeaways. * COMP360's possible FDA approval is key for Compass Pathways and its investment case. * Hiring and expansion show confidence while increasing exposure if approval fails. * Approval would create a new test: adoption, access and commercial execution. * Leadership must balance launch readiness with financial flexibility. Frequently asked questions. What is COMP360? It is Compass Pathways' synthetic psilocybin pill, developed for people with treatment-resistant depression. When could FDA approval happen? Business Insider reported that approval could come as soon as next year, after Compass completes its final filings. Why did Compass expand before approval? The company is preparing for a potential launch through new hiring, marketing expansion and new Jersey City offices. Those commitments create momentum but raise the cost of regulatory failure. What does approval not guarantee? Regulatory clearance does not by itself ensure broad prescribing, patient access or commercial success. Those outcomes require further execution. Related reading. Source & credits. This article was originally published by www.businessinsider.com. All images belong to the original publisher. Content and images remain (C) their respective owners and are shared here for informational, non-commercial purposes with full attribution.

After a long, strange trip, this CEO is close to taking a psilocybin pill to market. Oct 25, 2026, 7:07 AM PT In 2022, Kabir Nath had a cushy executive job at a pharmaceutical firm that developed anti-psychotic medication. Then he got a call from a scrappy upstart with a patent on a synthetic version of psilocybin - the active ingredient in magic mushrooms. It hoped to use the compound to help those with treatment-resistant depression. They wanted him to join as CEO. Nath, whose father died by suicide, bit on their second pitch. "A number of people have said to me in the last couple of years: 'You do realize what a risk that was,'" Nath told Business Insider about eventually jumping ship for what was, and still is, a drug company without FDA approval for its product. "I was probably the first really senior executive from traditional pharma to make the move to psychedelics," he added. "But, you know, it was the right thing to do." Nath's personal risk is now magnified as Compass Pathways finishes filing its final forms ahead of what could be FDA approval as soon as next year, and then a public rollout of its psilocybin pill, called COMP360. Compass has recently added 150 new hires to its payroll, expanded its marketing division, and moved into new office space in Jersey City in the hope it all works out. "The company is growing rapidly," Nath said. Though a subsidiary of Johnson and Johnson attained FDA approval with a version of ketamine for depression patients in 2019, it is by no means guaranteed that Compass, leveraging a more traditional psychedelic, will get the same approval. Should the FDA deny Compass' bid, investors would rush to dump their shares, likely sending the company into bankruptcy. The Jersey City office, which just received a new lime green paint job, would be untenable. If you ask Nath, it would also be bad news for 4 million patients with depression in the US, for whom more traditional antidepressants like SSRIs don't work. "These are people who have been suffering from depression, and nothing's really working," he said. Like other drug companies - especially those with a single product - Compass' stock has "been on quite the adventure," Nath said, as the company progressed through various human trials. When markets closed on Friday, the share price hovered around $11, up $5 from last year. In 2020, when the company went public, shares went for $17. From haight ashbury to wall street. Psilocybin's journey to the forefront of medical research didn't begin with Compass, and it hasn't exactly gone in a straight line. Few did more to publicize the drug than Timothy Leary, the Harvard professor turned acid dropout. In a speech at Harvard's Cambridge campus in 1962, he told students that taking psilocybin allows people to experience an "internal rebirth," according to the Harvard Crimson. In time, Leary would be fired from Harvard as he, along with a measurable portion of the US population, began to experiment more heavily with psychedelic drugs. Come 1966, the Grateful Dead were spiking their Kool-Aid with acid, and a definitive subculture of long-haired, psychedelic-taking hippies had emerged. Meanwhile, researchers were experimenting too. Studies involving LSD and psilocybin flourished during the 1960s before hitting a brick wall in 1970, when psilocybin was classified as a Schedule I substance, rendering possession illegal, even for research purposes. Work on the drug languished for years, until 2000, when the FDA gave scientists at Johns Hopkins University permission to conduct research on psilocybin. And more recently, psychedelics have become trendy with the tech crowd. From Burning Man to luxury retreats, experimenting with psychedelics is now common among tech founders and executives like Elon Musk and Sam Altman, who credit the drugs with quieting their nerves, boosting productivity, and allowing them to better harness their creativity. Research, too, has flourished. "There was actually a biotech boom from 2018 through to about 2022," Nath said. "In that boom, literally hundreds of psychedelic companies went public." In 2018, Compass' proprietary psilocybin formulation received breakthrough therapy designation from the FDA. A few years later, it started testing the drug on people. Nath was an executive in 2018 at Japanese pharmaceutical giant Otsuka, where he said he assembled a team to investigate whether psychedelics could become viable medicines after reading Michael Pollan's book "How to Change Your Mind," which explores the history and therapeutic potential of psychedelics. COMP360. Compass isn't selling an experience analogous to a spiritual awakening at Burning Man, though. The drug-taking process for a patient enrolled in one of Compass' trials is a bit different. First, a patient has to have treatment-resistant depression, which is clinically defined as depression that two or more standard drugs have failed to treat. Then, a clinician explains the details of the process that is about to unfold. After that, they're given the psilocybin in pill form. "It's a quiet room with a couch," Nath said. "They're offered a blindfold, which most patients do actually wear." As the patient begins to trip, a playlist of music, including classical and new age, plays softly in the background. The clinician, who Nath said could be a nurse, doctor, or therapist, sits silently in the room if the patient wants to talk, and for safety reasons. Most of the time, though, there isn't any talking. "This is not psychotherapy," Nath said. "We are not directing the patient's experience." Six hours later, after some crying, laughing, and everything in between, the patient goes home. In Compass's most recent trial, results for which were published in September, just under half of participants who took the drug experienced at least a 50% reduction in depressive symptoms within six weeks of treatment. Next steps. After a decade of slogging through tests, first on animals and then on humans, Compass has completed all the necessary prerequisites and is busily working to get its last papers in order. In a statement provided to Business Insider, an FDA spokesperson was noncommittal, though. "The FDA evaluates experimental medications, including psychedelic drugs like psilocybin, through a rigorous, evidence-based process designed to ensure that any approved treatment is safe and effective for the indicated use," the spokesperson said. Compass isn't the only psychedelic drug company wading through the lengthy process of trialing a drug. AtaiBeckley, another psychedelic drug company trading on the Nasdaq whose product is not yet approved by the FDA, is developing a version of DMT administered via nasal spray. It received breakthrough status in 2025, years behind Compass. For Compass, though, it could face the music as soon as the first half of next year, when it expects the FDA to render its decision. The company is already getting ready. In addition to adding 150 new hires, Nath said the company is preparing its sales force to go online and is in frequent communication with doctors and healthcare providers about operating in clinics where therapists can administer the drug to patients. "This has the potential to be radically different, and again, the rapidity is something that they're very excited about, and the durability," Nath said, referring to psychiatrists.